BGB-B2033
- Generic Name
- BGB-B2033
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Metastatic Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric CancerExtragonadal Yolk Sac TumorsGlypican-3 (GPC3)-Positive Squamous Non-small Cell Lung CancerMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 140
- Registration Number
- NCT06427941
- Locations
- 🇺🇸
Scri Oncology Partners, Nashville, Tennessee, United States
🇺🇸Upmc Hillman Cancer Center, Puyallup, Washington, United States
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath